Analytical Data
-
基因名
SIGLEC9/CD329
- Application
-
别名
SIGLEC9/CD329；Sialic acid-binding Ig-like lectin 9
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q9Y336
-
表达区间
18-348aa
-
氨基酸序列
ADPQTSKLLTMQSSVTVQEGLCVHVPCSFSYPSHGWIYPGPVVHGYWFRE GANTDQDAPVATNNPARAVWEETRDRFHLLGDPHTKNCTLSIRDARRSDA GRYFFRMEKGSIKWNYKHHRLSVNVTALTHRPNILIPGTLESGCPQNLTC SVPWACEQGTPPMISWIGTSVSPLDPSTTRSSVLTLIPQPQDHGTSLTCQ VTFPGASVTTNKTVHLNVSYPPQNLTMTVFQGDGTVSTVLGNGSSLSLPE GQSLRLVCAVDAVDSNPPARLSLSWRGLTLCPSQPSNPGVLELPWVHLRD AAEFTCRAQNPLGSQQVYLNVSLQSKATSGVTQGLEPKSCDKTHTCPPCP APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPA PIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVE WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPGKHHHHHH
-
分子量
66 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SIGLEC9, also known as CD329, is a member of the sialic acid-binding immunoglobulin-type lectins (SIGLECs) family, which play critical roles in the immune system by recognizing sialic acid-containing glycans on cell surfaces. Research into SIGLEC9 is particularly important due to its involvement in regulating immune responses, especially in the context of inflammation and cancer. Unlike other SIGLECs, SIGLEC9 is predominantly expressed on immune cells like monocytes, macrophages, and dendritic cells, influencing their activation and inhibitory signals. Studies have shown that SIGLEC9 can modulate T cell responses, promoting immune tolerance in certain contexts while potentially impeding anti-tumor immunity. This dual role highlights the necessity for a deeper understanding of SIGLEC9's functions and mechanisms to explore its therapeutic potential. The generation and characterization of recombinant SIGLEC9 proteins facilitate this research, allowing for better elucidation of its interactions with various ligands and pathways. Additionally, understanding the biochemical properties of SIGLEC9 could lead to novel strategies for manipulating immune responses in diseases such as cancer or autoimmune disorders. Therefore, the study of SIGLEC9/CD329 recombinant proteins holds promise for advancing immunotherapeutic approaches and enhancing our understanding of glycan-mediated immune modulation.
